Other Events ·
Tiziana reports positive Phase 2a INFORM-MS results for intranasal foralumab in na-SPMS
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences announced that its Phase 2a INFORM-MS trial of intranasal foralumab met primary endpoints, showing a statistically significant reduction in microglial activation on TSPO PET imaging (p=0.0168) at the 50μg dose and clinically meaningful improvements in fatigue across both dose arms after 12 weeks. The company plans to host a conference call with Key Opinion Leaders to discuss these findings, which support advancement toward a pivotal trial for non-active secondary progressive multiple sclerosis (na-SPMS). Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies.